Today: 21 May 2026
Nu Holdings stock dips as Nubank cools off from a 52-week high with U.S. jobs report ahead
7 January 2026
1 min read

Nu Holdings stock dips as Nubank cools off from a 52-week high with U.S. jobs report ahead

New York, January 7, 2026, 09:50 EST — Regular session

Nu Holdings Ltd shares slipped about 2.2% to $17.46 in early New York trade on Wednesday, backing away from recent highs after a strong start to the year.

The pullback comes with the stock still near its 52-week high — the best level in the past year — after a two-session sprint that briefly took it above $18.

Macro data is driving the mood. U.S. private payrolls rose by 41,000 in December, missing forecasts for a 47,000 gain, ADP’s report showed on Wednesday, a day before traders shift attention to Friday’s government jobs data.

Nu jumped 5.4% on Monday to close at $17.94 after touching $18.14, then eased 0.5% on Tuesday even as it hit $18.37, StockAnalysis.com data showed. Turnover cooled as well, with about 59 million shares traded on Tuesday versus roughly 79 million on Monday.

Other U.S.-listed Brazil fintech names were also lower: StoneCo fell about 6% and PagSeguro slid about 1.8% in early trading. In the sector backdrop, Brazilian digital bank PicPay filed for a U.S. IPO on Monday, a reminder that investor appetite for fintech paper has not vanished.

The next U.S. catalyst is close. The Bureau of Labor Statistics is due to release the Employment Situation report for December 2025 at 8:30 a.m. ET on Friday, with the Consumer Price Index for December 2025 set for Jan. 13.

But the setup cuts both ways. A hotter jobs print could push rate expectations and bond yields higher, a mix that can weigh on high-multiple growth stocks; and for digital lenders, any shift in credit quality can move the tape quickly.

Stock Market Today

  • Coca-Cola and Beverage Sector Show Mixed Q1 Performance with Vita Coco Leading Gains
    May 20, 2026, 9:22 PM EDT. As Q1 earnings wrap up, beverages, alcohol, and tobacco stocks report mixed results. The sector beat revenue estimates by 4.9%, though next-quarter guidance fell short by 0.6%. Coca-Cola (NYSE:KO) posted strong growth with $12.47 billion in revenue, exceeding estimates by 2.5%, and shares rose 7.7%. Leading the pack was Vita Coco (NASDAQ:COCO), with a 37.3% revenue surge and a 54.1% stock gain post-earnings. In contrast, Boston Beer (NYSE:SAM) saw a 4.4% revenue decline and missed on operating income forecasts, marking the weakest performance among peers. Shifting consumer trends and social media-driven lower brand launch costs are reshaping competition in the sector.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Cipla share price slides after USFDA flags Pharmathen: what the Form 483 says
Previous Story

Cipla share price slides after USFDA flags Pharmathen: what the Form 483 says

UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings
Next Story

UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings

Go toTop